The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo

Biomaterials

Volumn 32, Issue 10, 2011, Pages 2673-2682

  Nguyen, Ho Ngoc ^a   Wey, Shiaw Pyng ^b   Juang, Jyuhn Huarng ^b   Sonaje, Kiran ^a   Ho, Yi Cheng ^c   Chuang, Er Yuan ^a   Hsu, Chia Wei ^a   Yen, Tzu Chen ^b,d   Lin, Kun Ju ^b,d   Sung, Hsing Wen ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c VANUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Biodistribution; Chitosan; Insulin secretion; Oral delivery; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AFTER-TREATMENT; BIODISTRIBUTIONS; DIABETES PATIENTS; DIABETIC PATIENT; ENTERIC-COATED CAPSULES; IN-VIVO; INSULIN SECRETION; INSULINOTROPIC AGENTS; ORAL ADMINISTRATION; ORAL DELIVERY; PH SENSITIVE; PH-RESPONSIVE; PLASMA CONCENTRATION; POTENTIAL THERAPIES; SMALL INTESTINE; SPECT/CT; SYSTEMIC CIRCULATION; URINARY BLADDER;

BIOCHEMISTRY; CHITIN; CHITOSAN; DISSOLUTION; GLUCOSE; ISOTOPES; PH EFFECTS; PHARMACOKINETICS;

INSULIN;

EXENDIN 4; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EXCRETION; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; ENTERIC COATED CAPSULE; HUMAN; IN VIVO STUDY; INSULIN RELEASE; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STREPTOZOCIN DIABETES;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DRUG DELIVERY SYSTEMS; ELECTRIC IMPEDANCE; EPITHELIAL CELLS; FREEZE DRYING; HYDROGEN-ION CONCENTRATION; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MOLECULAR DYNAMICS SIMULATION; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; PHARMACEUTICAL VEHICLES; RATS; RATS, WISTAR; SOLUBILITY; STATIC ELECTRICITY; TABLETS, ENTERIC-COATED; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; VENOMS; WHOLE BODY IMAGING;

RATTUS;

EID: 79251593382     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.12.044     Document Type: Article

References (33)

1. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from heloderma suspectum venom. J Biol Chem 1992, 267(11):7402-7405.
2. Davidson M.B., Bate G., Kirkpatrick P. Exenatide. Nat Rev Drug Discov 2005, 4(9):713-714.
3. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117(2):77-88.
4. Gedulin B.R., Smith P.A., Jodka C.M., Chen K., Bhavsar S., Nielsen L.L., et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm 2008, 356(1-2):231-238.
5. Hamman J.H., Enslin G.M., Kotze A.F. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005, 19(3):165-177.
6. Lin Y.H., Chen C.T., Liang H.F., Kulkarni A.R., Lee P.W., Chen C.H., et al. Novel nanoparticles for oral insulin delivery via the paracellular pathway. Nanotechnology 2007, 18(10):105102.
7. Sonaje K., Lin Y.H., Juang J.H., Wey S.P., Chen C.T., Sung H.W. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009, 30(12):2329-2339.
8. Lin Y.H., Sonaje K., Lin K.M., Juang J.H., Mi F.L., Yang H.W., et al. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J Control Release 2008, 132(2):141-149.
9. Dodane V., Amin Khan M., Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999, 182(1):21-32.
10. Bowman K., Leong K.W. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 2006, 1(2):117-128.
11. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 2006, 58(15):1688-1713.
12. Chang L., Shepherd D., Sun J., Ouellette D., Grant K.L., Tang X., et al. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?. J Pharm Sci 2005, 94(7):1427-1444.
13. Marrink S.J., de Vries A.H., Mark A.E. Coarse grained model for semiquantitative lipid simulations. J Phys Chem B 2003, 108(2):750-760.
14. Nelson M.T., Humphrey W., Gursoy A., Dalke A., Kale L.V., Skeel R.D., et al. NAMD: a parallel, object-oriented molecular dynamics program. Int J Supercomput Appl High Perform Comput 1996, 10(4):251-268.
15. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983, 4(2):187-217.
16. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., et al. UCSF Chimera: a visualization system for exploratory research and analysis. J Comput Chem 2004, 25(13):1605-1612.
17. Chen M.C., Wong H.S., Lin K.J., Chen H.L., Wey S.P., Sonaje K., et al. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials 2009, 30(34):6629-6637.
18. Hilgers A.R., Conradi R.A., Burton P.S. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 1990, 7(9):902-910.
19. Sodoyez J.C., Sodoyez-Goffaux F., Guillaume M., Merchie G. [123I]Insulin metabolism in normal rats and humans: external detection by a scintillation camera. Science 1983, 219(4586):865-867.
20. Lin K.J., Liao C.H., Hsiao I.T., Yen T.C., Chen T.C., Jan Y.Y., et al. Improved hepatocyte function of future liver remnant of cirrhotic rats after portal vein ligation: a bonus other than volume shifting. Surgery 2009, 145(2):202-211.
21. Sonaje K., Lin K.J., Wey S.P., Lin C.K., Yeh T.H., Nguyen H.N., et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010, 31(26):6849-6858.
22. Khan M.Z.I., Prebeg Z., Kurjakovic N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers: I. manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. J Control Release 1999, 58(2):215-222.
23. O'Connor S.D., Summers R.M. Revisiting oral barium sulfate contrast agents. Acad Radiol 2007, 14(1):72-80.
24. Srinivasan K., Viswanad B., Asrat L., Kaul C.L., Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharm Res 2005, 52(4):313-320.
25. Jin C.H., Chae S.Y., Son S., Kim T.H., Um K.A., Youn Y.S., et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release 2009, 133(3):172-177.
26. Arnold F.H., Zhang J.H. Metal-mediated protein stabilization. Trends Biotechnol 1994, 12(5):189-192.
27. Varma A.J., Deshpande S.V., Kennedy J.F. Metal complexation by chitosan and its derivatives: a review. Carbohydr Polym 2004, 55(1):77-93.
28. Skovgaard M., Kodra J.T., Gram D.X., Knudsen S.M., Madsen D., Liberles D.A. Using evolutionary information and ancestral sequences to understand the sequence-function relationship in GLP-1 agonists. J Mol Biol 2006, 363(5):977-988.
29. Braier N.C., Jishi R.A. Density functional studies of Cu2+ and Ni2+ binding to chitosan. J Mol Struct (Theochem) 2000, 499(1-3):51-55.
30. Sonaje K., Lin K.J., Wang J.J., Mi F.L., Chen C.T., Juang J.H., et al. Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv Funct Mater 2010, 20(21):3695-3700.
31. Egan J.M., Clocquet A.R., Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002, 87(3):1282-1290.
32. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88(7):3082-3089.
33. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48(12):2270-2276.